Judgment of the General Court (Eighth Chamber) of 31 January 2018 –Novartis v EUIPO — SK Chemicals (Figurative EU trade mark representing a transdermal patch)
(Case T‑44/16)
(EU trade mark — Invalidity proceedings — Figurative EU trade mark representing a transdermal patch — Absolute ground for refusal — Sign consisting exclusively of the shape of the product necessary to obtain a technical result — Article 7(1)(e)(ii) of Regulation (EC) No 207/2009 (now Article 7(1)(e)(ii) of Regulation (EU) 2017/1001))
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Aim
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 17, 18, 57, 103)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Meaning—Two- or three- dimensional signs—Included
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see para. 19)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Meaning—Interpretation in the light of the public interest underlying each of them
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 20, 21)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Meaning—Existence of other shapes allowing the same technical result to be obtained—Not relevant to the ground for refusal
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 22, 36, 56, 79)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Identification of the essential characteristics of a sign
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 23, 24, 46, 47)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Assessment of the essential characteristics in the light of the technical function of the goods
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 25, 61, 68, 75)
- EU trade mark—Surrender, revocation and invalidity—Absolute grounds for invalidity—Registration contrary to Article 7(1)(e)(ii) of Regulation No 207/2009—Figurative mark representing a transdermal patch
(Council Regulation No 207/2009, Arts 7(1)(e)(ii) and 52(1)(a))
(see paras 38, 39, 52, 63, 69, 80, 90, 104)
- EU trade mark—Definition and acquisition of the EU trade mark—Assessment of the registrability of a sign—EU rules only taken into account—Earlier registration of the mark in certain Member States or third countries—Decisions not binding EU bodies
(Council Regulation No 207/2009)
(see para. 51)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Meaning—Presence of non-essential characteristics with no technical function—Not relevant to the ground for refusal
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 86, 101, 102)
- EU trade mark—Definition and acquisition of the EU trade mark—Absolute grounds for refusal—Signs which consist exclusively of the shape of goods which is necessary to obtain a technical result—Perception of the average consumer—Effect
(Council Regulation No 207/2009, Art. 7(1)(e)(ii))
(see paras 98, 99)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 27 November 2015 (Case R 2342/2014-5), relating to invalidity proceedings between SK Chemicals and Novartis.
Operative part
The Court:
-
Dismisses the action;
-
Orders Novartis AG to pay the costs.